Online inquiry

IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6837MR)

This product GTTS-WQ6837MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL3RA gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3563
UniProt ID P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6837MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6401MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ12883MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15193MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ7156MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ767MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ10001MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ283MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ13435MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW